Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Kristen Burock

Nurse Practitioner, Adult Health Canton, OH Nurse Practitioner

NPI 1467939371 CMS profile 10432252

1330 Mercy Dr Nw Ste 319, Canton, OH 44708

Open in the dashboard

General payments

$8,256

437 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Kristen Burock of Canton, OH is reported in the CMS Open Payments database as having received $8,256 across 437 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 95th percentile of Nurse Practitioner, Adult Health profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,003 60
2024 General $807 37
2023 General $1,443 86
2022 General $2,517 135
2021 General $2,485 119

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Kristen Burock
  • Nurse Practitioner, Adult Health median
  • Middle half of Nurse Practitioner, Adult Health
  • National median

In program year 2025, general payments to Kristen Burock were reported at $1,003. Among 12,696 Nurse Practitioner, Adult Health profiles paid that year, the median was $184 and the middle half received between $59 and $580.

Show as a table
Year Kristen Burock Nurse Practitioner, Adult Health median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $2,485 $138 $43–$438 $132
2022 $2,517 $165 $54–$494 $149
2023 $1,443 $178 $61–$549 $160
2024 $807 $186 $62–$575 $164
2025 $1,003 $184 $59–$580 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. GlaxoSmithKline, LLC. $1,743 120 payments
  2. AstraZeneca Pharmaceuticals LP $1,691 79 payments
  3. Boehringer Ingelheim Pharmaceuticals, Inc. $745 42 payments
  4. Inspire Medical Systems, Inc. $495 5 payments
  5. Regeneron Healthcare Solutions, Inc. $447 25 payments
  6. United Therapeutics Corporation $369 22 payments
  7. Jazz Pharmaceuticals Inc. $367 20 payments
  8. Actelion Pharmaceuticals US, Inc. $314 15 payments
  9. Genzyme Corporation $284 14 payments
  10. Electromed, Inc. $207 17 payments
  11. Other $1,595 78 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $8,256 437 payments
Products named General payments · program years 2021–2025
  1. NUCALA $1,132 67 payments
  2. FASENRA $991 34 payments
  3. BREZTRI $703 31 payments
  4. OFEV $601 39 payments
  5. TRELEGY ELLIPTA $487 50 payments
  6. DUPIXENT Inflammation And Immunology $403 23 payments
  7. OPSUMIT $314 15 payments
  8. SPIRIVA RESPIMAT $308 21 payments
  9. Inspire Upper Airway Stimulation System $306 2 payments
  10. DUPIXENT Immunology $284 14 payments
  11. Other $4,025 209 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 26 drugs

Part D claims

1,040

Median for Nurse Practitioner: 389

Drug cost

$398,571

Median for Nurse Practitioner: $21,885

Branded share of claims

67.3%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 114 $126,768
Fasenra Pen Benralizumab Brand 12 $68,375
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 58 $55,276
Spiriva Respimat Tiotropium Bromide Brand 38 $29,075
Breo Ellipta Fluticasone/Vilanterol Brand 25 $22,848
Anoro Ellipta Umeclidinium Brm/Vilanterol Tr Brand 25 $20,374
Symbicort Budesonide/Formoterol Fumarate Brand 47 $15,246
Stiolto Respimat Tiotropium Br/Olodaterol Hcl Brand 20 $15,131
Spiriva Handihaler Tiotropium Bromide Brand 11 $8,237
Budesonide-Formoterol Fumarate Budesonide/Formoterol Fumarate Brand 31 $6,242

The 10 drugs with the highest cost, of 26 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 8 billing codes

Paid by Medicare

$22,387

Medicare's payments for the services billed

Medicare patients

165

Average age 74

Services billed

389

86 women, 79 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
COPD 68%
Heart failure 52%
Ischemic heart disease 47%
Arthritis 42%
Chronic kidney disease 41%
Diabetes 40%
Atrial fibrillation 36%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 15 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
FASENRA
  • AstraZeneca Pharmaceuticals LP $201
$201 12 —
NUCALA
  • GlaxoSmithKline, LLC. $140
$140 — —
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $79
$79 — —
OPSUMIT
  • Actelion Pharmaceuticals US, Inc. $32
$32 — —
XYWAV
  • JAZZ PHARMACEUTICALS INC. $27
$27 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 15 in the dashboard with a free account

Records

437 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Adult Health in Ohio

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record